title: Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer.
abstract: Oncolytic viruses capable of tumor-selective replication and cytolysis have shown early promise as cancer therapeutics. We have developed replication-competent attenuated herpes simplex virus type 1 (HSV-1) mutants, named HF10 and Hh101, which have been evaluated for their oncolytic activities. However, the host immune system remains a significant obstacle to effective intraperitoneal administration of these viruses in the clinical setting. In this study, we investigated the use of these HSV-1 mutants as oncolytic agents against ovarian cancer and the use of human peritoneal mesothelial cells (MCs) as carrier cells for intraperitoneal therapy. MCs were efficiently infected with HSV-1 mutants, and MCs loaded with HSV-1 mutants caused cell killing adequately when cocultured with cancer cells in the presence or absence of HSV antibodies. In a mouse xenograft model of ovarian cancer, the injection of infected carrier cells led to a significant reduction of tumor volume and prolonged survival in comparison with the injection of virus alone. Our results indicate that replication-competent attenuated HSV-1 exerts a potent oncolytic effect on ovarian cancer, which may be further enhanced by the utilization of a carrier cell delivery system, based on amplification of viral load and possibly on avoidance of neutralizing antibodies.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Nagoya, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Fujiwara
authors.forename: A
authors.initials: A
authors.lastname: Nawa
authors.forename: C
authors.initials: C
authors.lastname: Luo
authors.forename: M
authors.initials: M
authors.lastname: Kamakura
authors.forename: F
authors.initials: F
authors.lastname: Goshima
authors.forename: C
authors.initials: C
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Kiyono
authors.forename: F
authors.initials: F
authors.lastname: Kikkawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nishiyama
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000235:genetics; D005260:Female; D018259:Herpesvirus 1, Human / Q000235:genetics* / Q000502:physiology; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy* / Q000821:virology; D014407:Tumor Cells, Cultured; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays